Compound News and Research

RSS

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Unique combination opens up novel applications in nano-engineering

Scientists from Ludwig-Maximilians-Universitaet in Munich have developed a new class of molecular motors that rotate unidirectionally at speeds of up to 1 kHz when exposed to sunlight at room temperature.

30 Sep 2015

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

David Griggs, Ph.D., director of biology at Saint Louis University's Center for World Health & Medicine, has received a $1 million R01 grant from the National Institutes of Health to investigate the development of what could be a new class of drugs to treat bone diseases.

30 Sep 2015

New software programs may help speed up drug discovery process for diabetes and other diseases

Proteins sometimes run amuck. All the good stuff (the useful genetic and biological material) they contain can get distorted. Mutations in specific amino acids can cause long strands of proteins to curl in on themselves (like a ball of wool a cat has played with) and refuse to break apart.

30 Sep 2015

Promising drug candidate for chronic intractable itch

If you have an itch, you have to scratch it. But that’s a problem for people with a condition called “chronic intractable itch,” where that itchy sensation never goes away—a difficult-to-treat condition closely associated with dialysis and renal failure.

28 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Stanford researchers successfully defeat C. difficile bacteria

Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug targeting its toxins rather than its life.

24 Sep 2015

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

The National Institutes of Health has awarded $346,000 to Worcester Polytechnic Institute for a three-year research project to advance development of a chemical process that could significantly improve the ability to design new pharmaceuticals and streamline the manufacturing of existing drugs.

24 Sep 2015

Researchers develop promising metal-based compound to fight kidney cancer

Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.

24 Sep 2015

TSRI scientists awarded grant from Gates Foundation to develop revolutionary alternative HIV/AIDS vaccine

Scientists from the Florida campus of The Scripps Research Institute have been awarded up to nearly $6 million dollars from the Bill & Melinda Gates Foundation to develop a revolutionary HIV/AIDS alternative vaccine that has demonstrated great potential in animal models.

23 Sep 2015

TTUHSC El Paso researcher awarded $375,000 grant to develop genetically altered TB vaccines

A $375,000 grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation was awarded to Subramanian Dhandayuthapani, Ph.D., an associate professor in the Center of Emphasis in Infectious Diseases at the Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, to develop genetically altered vaccines against tuberculosis (TB).

23 Sep 2015

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Longing to find a cure for cancer, HIV and other yet incurable diseases, researchers have already tried out hundreds of drugs, each requiring preclinical and clinical testing with live subjects. How many chemical agents more to try? Moving at such rate, will we find the cure during our lifetime? One of the easiest ways to speed up the drug development process is to simply perform it outside of the living body (e.g., by watching the substances react with the smallest pieces of live tissue and thus quickly predicting the overall effect it will make to the body when inside).

23 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA.

22 Sep 2015

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.

21 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015

Pipetting Solutions for Sample Screening

Our research focuses on interleukin 1 and the inflammasome and their role in innate immunity and inflammation.

From INTEGRA Biosciences 16 Sep 2015

Compound News and Research

Leading cancer researchers address eight 'big questions'

Unique combination opens up novel applications in nano-engineering

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

New software programs may help speed up drug discovery process for diabetes and other diseases

Promising drug candidate for chronic intractable itch

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Stanford researchers successfully defeat C. difficile bacteria

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

Researchers develop promising metal-based compound to fight kidney cancer

TSRI scientists awarded grant from Gates Foundation to develop revolutionary alternative HIV/AIDS vaccine

TTUHSC El Paso researcher awarded $375,000 grant to develop genetically altered TB vaccines

Novel graphene oxide-based biosensor may speed up development of new drugs against HIV, cancer

Drug combination delivers effective punch against one form of pancreatic cancer

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Vaginal silicone ring may protect women against HIV, herpes virus

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Pipetting Solutions for Sample Screening

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News